Status:
COMPLETED
Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in the Treatment of First Episode Nonaffective Psychosis
Lead Sponsor:
Fundación Marques de Valdecilla
Collaborating Sponsors:
Centro de Investigación Biomédica en Red de Salud Mental
Instituto de Investigación Marqués de Valdecilla
Conditions:
Schizophrenia
Psychotic Disorders
Eligibility:
All Genders
15-60 years
Phase:
PHASE4
Brief Summary
The selection of antipsychotic in early stages of the illness is mainly determined by its clinical effectiveness. Second generation antipsychotics (SGAs) are the first line drug treatment for individu...
Detailed Description
Study setting and financial support: data for the present investigation were obtained from an ongoing epidemiological and three-year longitudinal intervention program of first-episode psychosis (PAFIP...
Eligibility Criteria
Inclusion
- 15-60 years.
- Living in the catchment area.
- Experiencing their first episode of psychosis.
- No prior treatment with antipsychotic medication or, if previously treated, a total life time of adequate antipsychotic treatment of less than 6 weeks.
- Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria for brief psychotic disorder, schizophreniform disorder, schizophrenia, or schizoaffective disorder.
Exclusion
- Meeting DSM-IV criteria for drug dependence
- Meeting DSM-IV criteria for mental retardation
- Having a history of neurological disease or head injury.
Key Trial Info
Start Date :
October 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2014
Estimated Enrollment :
203 Patients enrolled
Trial Details
Trial ID
NCT02305823
Start Date
October 1 2005
End Date
May 1 2014
Last Update
March 14 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Marques de Valdecilla
Santander, Cantabria, Spain, 39008